Tempus Resources (TMRR.V) is an illiquid stock, a gold explorer in a vortex. On a regular day, the stock sits and waits. On an irregular day, it stretches for…
ASX
We’re back with the fumble. Last week I was indisposed, apologies. A sexy nurse was slicing open my right arm and stuffing a camera through the artery all the…
Hemp is hot and Elixinol Global (EXL.ASX) is riding the wave Hemp, the perennially uncool cousin of Mary Jane is staging something of a comeback. Often touted as an…
Muay Thai is the national sport here in my adopted homeland. Known as ‘the science of eight limbs‘ it’s a brutal contest – a knee or elbow to the…
I still remember what it felt like to wake up and realize it was Friday when I was entombed in a corporate cubicle. Everything was sweeter – even the…
It’s been a long ten months for CannPal Animal Therapeutics (CP1.ASX) shareholders having watched their investment hover around the $0.20 IPO issue price. While other ASX cannabis names have…
On the surface, the rights issue announced by Creso Pharma (CPH.ASX) looks to be a decent deal for long-suffering shareholders, albeit it a little unusual. The rights issue is…
The Australian government has really dropped the ball when it comes to easy access to medicinal cannabis. Want proof? Sometimes all you need is a picture, like the one…
So Auscann (AC8.ASX) has finally released the details of their share purchase plan (SPP) and retail have been shafted, yet again. Here are the main points: AUD $1.05 issue…
AusCann (AC8.ASX) shares were placed in a trading halt Tuesday July 3, 2018 as the AFR Street Talk column reported the company was seeking to raise $30 million from…